Business
Cannabics Pharmaceuticals Files Provisional Patent on Composition and Method for Treating Colon Cancer With Cannabinoids
Cannabics Pharmaceuticals Files Provisional Patent on Composition and Method for Treating Colon Cancer With Cannabinoids.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Files Provisional Patent on Composition and Method for Treating Colon Cancer With Cannabinoids\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Files Provisional Patent on Composition and Method for Treating Colon Cancer With Cannabinoids\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, May 6, 2020\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, May 6, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has filed a Provisional Patent Application with the US Patent & Trademark Office (USPTO) entitled \"Composition and Method for Treating Colon Cancer with Cannabinoids\".\n\n \n \n \n \n \n \n\n \nThe application specifically targets Colon Cancer and follows the Company's preclinical development of a novel formulation containing various cannabinoids which have been shown to demonstrate anti-tumor properties in studies focused on gastrointestinal cancers.\nThe composition contains high concentrations of the cannabinoids in a proprietary formulation. Having demonstrated complex combinatorial anti-tumor effects and lacking psychoactive effects, the composition may enable patients to be treated with high dosages without intoxication.\nThe company plans to examine the clinical safety and efficacy of the novel formulation in clinical studies in Israel where regulation permits the clinical validation process through GMP certified cannabis-based products. \nAbout Cannabics Pharmaceuticals\nCannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S public company that is developing a platform that leverages novel drug-screening tools to create cannabinoid-based therapies for cancer that are more precise to a patient's profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientif...